Promatix

Promatix is a data-driven company that leverages multi-omics information to develop a robust pipeline of novel therapies with the potential to transform cancer treatment. Promatix will utilize its proprietary multi-omics database, TxPro, to mine for novel drug targets and validate existing ones. In the near term, Promatix will continue to be incubated within the ALSA Group, which will provide seed funding to establish its first set of target research programs. We have a particular interest in proteomics and integrating it with other forms of omics data to gain deep insights into how this information changes in health and disease. Promatix will combine its proprietary platform, TxPro, with third-party public and private databases to create a powerful multi-omics engine to help identify new targets and accelerate early-stage development.